Tolerance profile of the proliferation signal inhibitors @entity2239 and XXXX in heart transplantation.

@entity1 @entity8 @entity5 @entity4 @entity294 @entity3446 @entity2239 @entity281 @entity299
INTRODUCTION: The side effects of proliferation signal inhibitors (PSIs) have been characterized as a class. However, it would be convenient to assess them according to the molecule. OBJECTIVE: To assess prospectively the tolerance of PSIs among @entity299 ( @entity299 ) @entity1 . @entity1 AND METHODS: We studied 56 @entity299 @entity1 who sequentially received PSIs to either withdraw (77%) or reduce the dosage of a calcineurin inhibitor; 42 received @entity2239 (EVE) and 14 @entity3446 (SRL). We analyzed the demographic variables, side effects, and need to withdraw the drug during a median follow-up period of 365 days. RESULTS: No differences between groups were observed upon analysis of the clinical and demographic variables when the treatment was changed owing to @entity8 (67%) or @entity5 (32%). No difference between groups was observed over the follow-up period (P = .28). Infection was the most common side effect, 28.6%: EVE, 14.3% versus SRL, 71.4% (P < .0001). @entity4 occurred in 26.8% of @entity1 : EVE, 14.3% versus SRL, 64.3% (P = .001); @entity294 in 5.4% of @entity1 : EVE, 2.4% versus SRL, 14.3% (P = .15). Treatment was withdrawn in 23.2% of the @entity1 due to intolerance: EVE, 11.9% versus SRL, 57.1% (P < .0001). EVE showed significantly better survival without @entity4 or @entity281 or used for drug withdrawal upon Kaplan-Meier analysis, (P = .01; P = .0005; P = .0097). Only SRL use was shown to be an independent predictor of side effects. CONCLUSION: @entity4 and @entity281 are the main problems caused by PSIs. EVE may display a better tolerance profile than SRL.
